FDBusiness.com

DuPont Nutrition & Health and Inbiose Partner to Bring Novel Infant Nutrition Ingredients to Market

 Breaking News
  • Record UK Grocery Sales as Shoppers Prepare For Lockdown Facebook Twitter LinkedIn The latest UK grocery market share figures from Kantar show year-on-year supermarket sales grew by the fastest rate in over a decade during the past 12 weeks...
  • AB InBev Withdraws 2020 Outlook Facebook Twitter LinkedInGiven the uncertainty, volatility and fast-moving developments of the COVID-19 pandemic in the markets in which AB InBev operates, the global brewer has withdrawn its 2020 Outlook, which...
  • Teknomek hits peak design with new Dyson Airblade wash troughs Facebook Twitter LinkedInHygienic furniture specialist Teknomek has introduced new Dyson Airblade wash trough models that have been developed to reduce listeria risk in food processing facilities. Variants of the product...
  • Greencore Names New CFO Facebook Twitter LinkedIn The Board of Greencore Group, a leading manufacturer of convenience food in the UK, has announced the appointment of Emma Hynes (pictured) as Executive Director and Chief...
  • Müller UK & Ireland Launches Major Recruitment Drive to Help Feed the Nation Facebook Twitter LinkedInThe UK’s favourite dairy brand[1] has launched a significant recruitment push for up to 300 additional key workers to help feed the nation. This follows strong consumer demand for...

DuPont Nutrition & Health and Inbiose Partner to Bring Novel Infant Nutrition Ingredients to Market

DuPont Nutrition & Health and Inbiose Partner to Bring Novel Infant Nutrition Ingredients to Market
November 16
10:49 2016

DuPont Nutrition & Health has entered a joint development and licensing agreement for exclusive rights to selected fucosylated human milk oligosaccharides (HMOs), including 2’ -fucosyllactose, with Inbiose, a Belgium-based producer of specialty carbohydrates.

HMOs are a group of unique oligosaccharides found in mother’s milk, with 2’-fucosyllactose being the single most abundant HMO. This new partnership combines Inbiose’s innovative production platform for specialty carbohydrates with DuPont’s capabilities in industrial-scale fermentation, regulatory and health science expertise, as well as global market access.

“This partnership is part of a new era in ingredients targeted for infant nutrition,” says John Rea, global business unit leader for Probiotics, Cultures, Food Protection and HMOs at Du Pont. “With this development, we’re working toward fulfilling our corporate mission to help solve the world’s food challenges by providing innovative ingredients our customers can use to make healthy and nutritious products. Our investment here complements the broad capabilities DuPont has built in probiotics and understanding the human gut microbiome, as well as our technologies already targeting this area.”

The partnership is currently focusing on developing the ingredients for market introduction by implementing an industrial-scale fermentation process and submission for regulatory approvals to enter the market in 2017. “We are excited to collaborate with Inbiose and bring the science of HMOs to market,” says Martin Kullen, global R&D leader for Probiotics, Cultures, Food Protection and HMOs at Du Pont. “HMOs are key in helping our customers move another step closer to matching the composition of human milk with their infant nutrition products.”

HMOs have been identified as important components of human milk that help shape an infant’s gut microbiome and a balanced immune system development. A growing body of evidence suggests that HMOs benefit the health of developing infants by supporting digestive, immune and cognitive development[1].

“Our collaboration with DuPont, a world-renown ingredient manufacturer, advances our technology and will accelerate the introduction of our first HMO to improve the health and well-being of infants,” says Professor Wim Soetaert, executive chairman of Inbiose.

Digestive/gut health was the primary claim associated with infant formula launches in 2015, according to market research firm Innova2. It was featured on 58 percent of all launches in the market. Over the past five years, the use of prebiotics in infant formulas has dramatically increased.

“HMOs are found naturally in mother’s milk and represent the next generation of functional oligosaccharides. The inclusion of HMOs will be a significant advancement in the improvement of infant formula,” says Martin Kullen. “With our experience delivering products to the strict safety and efficacy standards required for the infant formula segment, DuPont will be at the forefront of commercializing HMOs.”

[1] Bode, L. (2015). The functional biology of human milk oligosaccharides. Early Human Development, 91, first 619-622.

2 Formulation Trends in Baby Formula/Milk”, March 2016, Innova Market Insights.

About Author

mike

mike

Related Articles

Food & Drink Business Conference & Exhibition 2016

find food jobs

The Magazine

F&D Business Preferred Suppliers

New Subscriber

Subscribe Here



Advertisements